RecruitingRecruiting
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
NCT06906471 · Antelope Surgical Solutions, Inc
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
About this study
A Single-Arm, blinded, fluorescent PSMA histopathology trial of AS1986NS
Eligibility criteria
Inclusion Criteria:
* suspected prostate cancer warranting standard of care multi-core prostate biopsy
Exclusion Criteria:
* Patients receiving same-day therapeutic Lutetium-177 or Actinium-225 PSMA receptor radiation isotope therapy treatment
* Patients with pre-existing, impaired or abnormal hepatic function, renal function, cardiac function, and abnormal elevated temperature
* Patients with a creatinine clearance cutoff (CrCl) of \< 60 mL/min
Study design
Enrollment target: 10 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-07-01
Estimated completion: 2026-12-30
Last updated: 2026-07-09
Interventions
Drug: AS1986NS
Primary outcomes
- • Safety of AS1986NS (Enrollment to 30 days post single infusion)
Sponsor
Antelope Surgical Solutions, Inc · industry
Contacts & investigators
ContactAmy Wu, MD · contact · info@antelopesurgical.com · 917-960-8876
All locations (2)
HCA Florida Kendall HospitalRecruiting
Miami, Florida, United States
Icahn School of Medicine at Mount Sinai (ISMMS)Not Yet Recruiting
New York, New York, United States